Publications

Perspectives on the development of new antimicrobial agents for resistant Gram-positive pathogens. by Jones RN published in Braz. J. Infect. Dis. 2000; 4 (1): 1-8

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. by Gales AC and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (1): 19-36

Oxazolidinones: A review. by Diekema DI and Jones RN published in Drugs 2000; 59 (1): 7-16

Microbiology of infections in the coronary care unit. by Diekema DJ and Jones RN published in Antibiotics for Clinicians2000; 4 (Suppl 1): 5-10

Russian Klebsiella pneumoniae isolates that express extended-spectrum β-lactamases. by Winokur PL, Eidelstain MV, Stetsiouk O, Stratchounski L, Blahova J, Reshedko GK, Croco MA, Hollis RJ, Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2000; 6 (2): 103-108

Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. by Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, Marshall SA and Jones RN published in J. Clin. Microbiol. 2000; 38 (5): 1818-1822

Pharyngeal colonization prevalence rates for Streptococcus pyogenes and Streptococcus pneumoniae in a respiratory chemoprophylaxis intervention study using azithromycin. by Putnam SD, Gray GC, Biedenbach DJ and Jones RN published in Clin. Microbiol. Infect. 2000; 6 (1): 2-8

Evaluation of the discriminatory powers of the Dienes test and ribotyping as typing methods for Proteus mirabilis. by Pfaller MA, Mujeeb I, Hollis RJ, Jones RN and Doern GV published in J. Clin. Microbiol. 2000; 38 (3): 1077-1080

Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. by Pfaller MA, Messer SA, Houston A, Mills K, Bolmstrom A and Jones RN published in J. Clin. Microbiol. 2000; 38 (10): 3715-3717

Global trends in an antimicrobial resistance surveillance system: Results from the MYSTIC Programme. by Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2000; 6 (Suppl 1): 74

Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications. by Odland BA, Erwin ME and Jones RN published in J. Clin. Microbiol. 2000; 38 (1): 453-455

Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent. Quality Control Study Group. by Marshall SA, Erwin ME, and Jones RN published in J. Clin. Microbiol. 2000; 38 (6): 2462-2463

Evaluation of quinupristin/dalfopristin (Synercid) and RPR 106972 stability in susceptibility testing media. by Marshall SA, Kugler KC, and Jones RN published in Int. J. Antimicrob. Agents 2000; 15 (4): 291-297

Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection. by Lewis RE, Klepser ME, Ernst EJ, Snabes MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (1): 51-55

Anti-gonococcal activity of gemifloxacin against fluoroquinolone- resistant strains and a comparison of agar dilution and Etest methods. by Jones RN, Deshpande LM, Erwin ME, Barrett MS and Beach ML published in J. Antimicrob. Chemother. 2000; 45 (Suppl 1): 67-70

Cefditoren activity against nearly 1,000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. by Jones RN, Biedenbach DJ and Johnson DM published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 143-146

Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group. by Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 2000; 37 (3): 195-201

Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and Etest method validation. Quality Control Study Group. by Jones RN, Johnson DM, Erwin ME, Beach ML, Biedenbach DJ and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1999; 34 (2): 91-98

The impact of antimicrobial resistance: Changing epidemiology of community-acquired respiratory-tract infections. by Jones RN published in Am. J. Health Syst. Pharm. 1999; 56 (22 Suppl 3): S4-S11

Disk diffusion susceptibility test development for the new glycylcycline, GAR-936. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (3): 249-252

Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. by Johnson DM, Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1999; 33 (2): 87-91

Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates. by Hayward CL, Erwin ME, Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 34 (2): 99-102

Practical approach to the identification of clinically relevant Enterococcus species. by Willey BM, Jones RN, McGeer A, Witte W, French G, Roberts RB, Jenkins SG, Nadler H and Low DE published in Diagn. Microbiol. Infect. Dis. 1999; 34 (3): 165-171

Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group. by Erwin ME and Jones RN published in J. Clin. Microbiol. 1999; 37 (1): 279-280

Phenotypic and genotypic characterizations of Chinese strains of Escherichia coli producing extended-spectrum β-lactamases. by Shen D, Biedenbach DJ, Winokur PL, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 34 (3): 159-164

Nosocomial bloodstream infections in United States hospitals: A three- year analysis. by Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN and Wenzel RP published in Clin. Infect. Dis. 1999; 29 (2): 239-244

Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: Potential human-to-animal transmission. by Seguin JC, Walker RD, Caron JP, Kloos WE, George CG, Hollis RJ, Jones RN and Pfaller MA published in J. Clin. Microbiol. 1999; 37 (5): 1459-1463

Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: A report from the College of American Pathologists Microbiology Proficiency Survey Program. by Doern GV, Brueggemann AB, Pfaller MA and Jones RN published in Arch. Pathol. Lab. Med. 1999; 123 (4): 285-289

Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. by Saiman L, Burns JL, Whittier S, Krzewinski J, Marshall SA and Jones RN published in J. Clin. Microbiol. 1999; 37 (9): 2987-2991

Comparison of activities of broad-spectrum β-lactam compounds against 1,128 Gram-positive cocci recently isolated in cancer treatment centers. by Diekema DJ, Coffman SL, Marshall SA, Beach ML, Rolston KV and Jones RN published in Antimicrob. Agents Chemother. 1999; 43 (4): 940-943

Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. by Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME and Hajjeh RA published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 217-222

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer treatment centers. by Diekema DJ, Jones RN and Rolston KV published in Diagn. Microbiol. Infect. Dis. 1999; 34 (1): 37-43

Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: Disk diffusion/Etest method evaluations and quality control guidelines. The Quality Control Study Group. by Marshall SA, Jones RN, and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1999; 33 (1): 19-25

Colony morphology of Candida spp. as a guide to species identification. by Buschelman B, Jones RN, Pfaller MA, Koontz FP and Doern GV published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 89-91

Spectrum and antimicrobial activity of alexomycin (PNU-82, 127), a peptide compound projected for use in animal health. by Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 33 (3): 181-186

Accuracy of cefepime antimicrobial susceptibility testing results for Pseudomonas aeruginosa tested on the MicroScan WalkAway System. by Biedenbach DJ, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 305-307

Ability of the modified Vitek card to detect coagulase-negative staphylococcal with mec A and oxacillin-resistant phenotypes. by Marshall SA, Pfaller MA and Jones RN published in J. Clin. Microbiol. 1999; 37 (6): 2122-2123

Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. by Kugler KC, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 34 (1): 73-76

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: The role of streptogramins and other newer compounds. by Jones RN, Low DE and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1999; 33 (2): 101-112

Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-µg) diffusion methods. The Quality Control Study Group. by Jones RN, Kugler KC, Erwin ME, Biedenbach DJ, Beach ML and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1999; 33 (4): 247-253

Combinations of orally administered β-lactams to maximize spectrum and activity against drug-resistant respiratory tract pathogens: I. Synergy studies of amoxicillin and cefixime with Streptococcus pneumoniae. by Jones RN and Johnson DM published in Diagn. Microbiol. Infect. Dis. 1998; 31 (2): 373-376

Bacterial resistance: A worldwide problem. by Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 1998; 31 (2): 379-388

Activity of a broad-spectrum cephalosporin (RO 48-8391) alone and in combination with two novel β-lactamase inhibitors (RO 48-5545 and RO 48-8724). by Jones RN, Marshall SA and Varnam DJ published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 85-94

Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime. by Jones RN, Biedenbach DJ, Marshall SA, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 107-110

Antimicrobial interactions of trovafloxacin and extended-spectrum cephalosporins or azithromycin tested against clinical isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. by Johnson DM, Jones RN and Pfaller MA published in J. Antimicrob. Chemother. 1998; 42 (4): 557-559

International multicenter investigation of LB20304, a new fluoronaphthyridone. by Hohl AF, Frei R, Punter V, von Graevenitz A, Knapp C, Washington J, Johnson D and Jones RN published in Clin. Microbiol. Infect. 1998; 4 (5): 280-284

Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. by Biedenbach DJ, Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 31 (2): 349-353

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. by Biedenbach DJ, Barrett MS, Croco MA, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (1): 45-50

Antimicrobial activity of gatifloxacin tested against Neisseria gonorrhoeae using three methods and a collection of fluoroquinolone-resistant strains. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 32 (4): 307-311

Timed kill kinetic studies of levofloxacin, ofloxacin, and ciprofloxacin against Moraxella catarrhalis. by Barrett MS and Jones RN published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 135-137